Magazine
Sign up for your free subscription and keep up-to-date.
Upcoming Events
Newsletters
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
Clinical Trials
|
July 03 2007
ViRexx licensing partner presents OvaRex(R) MAb Phase II trial results ViRexx Medical Corp. announce the results from a Phase II trial of OvaRex(R) MAb conducted by ViRexx's licensing partner, Unither Pharmaceuticals, Inc. (Unither), a subsidiary of United Therapeutics Corporation.
|
|
June 21 2007
Clinical Trials & Patents AEterna Zentaris (Quebec City, QC) reports dosing has commenced with its flagship product candidate, cetrorelix, the company's lead luteinizing hormone-releasing hormone (LHRH) antagonist compound, in the first study of its Phase III program in benign prostatic hyperplasia (BPH).
|
|
June 01 2007
Oncolytics begins patient enrolment in clinical trial Oncolytics Biotech Inc. has commenced patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced cancers including head and neck, melanoma, lung and ovarian. It is one of three trials expected to begin in 2007 that will examine the role of REOLYSIN(R) in combination with standard chemotherapeutics.
|
|
May 14 2007
Generex Biotechnology Enters Into Agreement Generex Biotechnology Corporation announces that it has entered into an agreement with the Lebanese-Canadian Hospital in Beirut, Lebanon to conduct a human clinical trial of the Antigen Express synthetic avian influenza vaccine
|
|
May 14 2007
Cytochroma Inc. announces clinical trial enrollment Cytochroma Inc. announces that it has completed the enrollment of patients in a Phase II clinical trial of CTA018 Cream.
|
|
May 14 2007
Exelixis delays new enrolment clinical trial Exelixis says it will delay new enrolment for a clinical trial of the cardiovascular drug XL999 for up to three months.
|
|
May 14 2007
Favrille announces Trial Results Favrille announces results from a Phase II trial of 103 patients treated with FavId following Rituxan showed an increase in overall clinical response rate to 64% versus 49% following Rituxan alone.
|
|
May 11 2007
Protox doses first patient in benign prostatic hyperplasia trial using PRX302 Protox Therapeutics Inc. enjoys successful dosing of the first patient in a Phase I clinical study evaluating PRX302 to treat benign prostatic hyperplasia (BPH), commonly called enlarged prostate, a disease that affects one million Canadian men.
|
|
April 25 2007
Viventia Biotech initiates patient treatment for Vicinium(TM) Phase II bladder cancer trial Viventia Biotech Inc. has initiated patient treatment in its open-label Phase II clinical trial for Vicinium(TM), administered using intravesical instillation for the treatment of locally persistent non-invasive bladder cancer.
|
|
April 13 2007
Migenix Inc. demonstrates Phase II study benefit Migenix Inc. demonstrated proof-of-concept and evidence of clinical benefit in a Phase II study using oral alpha-glucosidase inhibitor.
|
|
April 13 2007
Vasogen Inc. announces new technology at trial session Vasogen Inc. announces that its Celacade technology in chronic heart failure was presented at the late breaking clinical trial session of the 2006 Canadian Cardiovascular Congress in Vancouver, BC.
|
|
April 13 2007
Isotechnika Inc. reports final data Isotechnika Inc. reports final safety and efficacy data subsequent to 60 weeks of continuous treatment with ISA247.
|
|
April 13 2007
Liponex Inc. clinical protocol Liponex Inc. announces that it will modify the clinical protocol for its ongoing Phase I/II clinical trails for its lead product, CRD5.
|
|
April 13 2007
Allon Therapeutics announces IND filing Allon Therapeutics Inc. announces that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA), seeking approval to begin human clinical trials evaluating the company's product AL-108 as a treatment for Schizophrenia related cognitive impairment.
|
|
April 05 2007
Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 Liponex Inc. announces results of the Phase I/II Clinical Trial of its lead product, CRD5. CRD5 is being developed for the treatment of dyslipidemia and heart disease. Results showed, to date, that CRD5 was safe and that the drug formulation was stable throughout the trial.
|
|
April 05 2007
Ondine demonstrates high Periowave(TM) efficacy in key tissue-invasive pathogen Ondine Biopharma Corporation recently performed a presentation of a late-breaking abstract at the prestigious International Association of Dental Research (IADR) annual meeting in New Orleans. This publication showed that the Periowave(TM) photodisinfection system is capable of eradicating one of the most elusive and difficult to kill periopathogens, Actinobacillus actinomycetemcomitans (Aa).
|
|
April 04 2007
FDA grants fast track designation to Alzheimer's disease drug candidate Transition Therapeutics Inc. announces that the United States Food and Drug Administration has granted fast track designation to investigational drug candidate AZD-103/ELND005.
|
|
March 12 2007
Ondine announces positive clinical results Ondine Biopharma Corporation announces that the publication of three Periowave clinical trial abstracts will be presented at the combined meetings of the International Association for Dental research (IADR) and the American Association for Dental Research (AADR) in New Orleans this month.
|
|
March 12 2007
Neptune Releases Final ADHD Study Results Showing Significant Benefits Neptune Technologies & Bioressources Inc. announces very positive final results of the effect of Neptune Krill Oil (NKO) on adult Attention Deficit Hyperactivity Disorder (ADHD).
|
|
March 12 2007
Pacific Therapeutics Ltd. Teams Up with UBC for Study Pacific Therapeutics Ltd. enters into an eight-month contract with UBC to perform animal studies with the companys lead candidate, PTL-101.
|
|
March 09 2007
ProMetic announces approval program expansion ProMetic Life Sciences Inc. announces the receipt of regulatory approval from Health Canada for the expansion of its lead compound PBI-1402's clinical program
|
|
March 09 2007
Allon Therapeutics progresses into clinical trial Allon Therapeutics Inc. progressed into the randomized portion of its Phase II human clinical trial.
|
|
March 09 2007
Vanda Pharmaceuticals buoyed by latest data Vanda Pharmaceuticals was buoyed by the latest data from a late-stage clinical trial of its experimental insomnia therapy.
|
|
March 09 2007
Isotechnika Inc. announces kidney transplant trial results Isotechnika Inc. announces results from initial data for its Phase IIb kidney transplant trial.
|
|
February 23 2007
Allon files IND for approval of Schizophrenia Phase II clinical trials Allon Therapeutics Inc. announces that it has filed an Investigational New Drug application (IND) with the United State Food and Drug Administration (FDA) seeking approval to begin human clinical trials evaluating the companys product AL-108 as a treatment for Schizophrenia related cognitive impairment.
|
|
February 05 2007
Allon confirms progress in AL-208 Phase II clinical trial Allon Therapeutics Inc. announces that it has progressed into the randomized portion of its Phase II human clinical trial evaluating the Company's product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery. The Company also announced the selection of the 300 mg dose, the highest one tested, in the randomized portion of the trial.
|
|
February 01 2007
Liponex Inc. Suspends Patient Treatment Liponex Inc. has suspended patient treatment at the highest dose level of 5 grams per day in a Phase I/II clinical trial for its lead product, CRD5.
|
|
February 01 2007
Biomira Inc. begins patient enrolment Biomira Inc. has begun patient enrolment in a global Phase III clinical trial to assess the efficacy and safety of Stimuvax® as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC).
|
|
February 01 2007
Abraxis BioScience Inc. plans to initiate a worldwide head-to-head Phase III Trial Abraxis BioScience Inc. plans to initiate a worldwide head-to-head Phase III registration trial comparing weekly Abraxanetm to every three week Taxotere® (docetaxel) for the treatment of first-line metastatic breast cancer.
|
|
February 01 2007
BioMS Medical Corp. continues clinical trial BioMS Medical Corp. will continue its Phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis following clearance from the independent Data Safety Monitoring Board (DSMB).
|
|
February 01 2007
Allon Therapeutics Inc. Receives Enrolment Approval Allon Therapeutics Inc. has received Institutional Review Board approval to begin enrolment.
|
|
January 30 2007
Allon confirms progress in AL-208 Phase II clinical trial Allon Therapeutics Inc., The Neuro Protection CompanyTM, announces that it has progressed into the randomized portion of its Phase II human clinical trial evaluating the Companys product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery.
|
|
January 30 2007
Ondine announces positive clinical results from its Periowave(TM) trial of maintenance therapy Ondine Biopharma Corporation announces that the publication of three Periowave(TM) clinical trial abstracts will be presented at the combined meetings of the International Association for Dental Research (IADR) and the American Association for Dental Research (AADR) meeting in New Orleans, March 21-24, 2007.
|
|
January 15 2007
ProMetic Life Sciences Inc. PBI-1402 enters clinical trial for anemia associated with chronic kidney disease ProMetic Life Sciences Inc. announces that it has received regulatory approval from Health Canada for the expansion of its lead compound PBI-1402s clinical program to include the treatment of anemic patients with Chronic Kidney Disease (CKD).
|
|
January 11 2007
Generex Reports Positive Findings Generex Oral-lyn, an oral insulin spray from Generex Biotechnology Corp. could be more effective than mealtime injections.
|
|
January 11 2007
Resverlogix Corp. Concludes RVX-208 Study A recent study has concluded that Resverlogix Corp.'s clinical candidate, RVX-208, can rapidly increase plasma levels of ApoA-I up to 150% relative to control animals in the first 24 hours.
|
|
January 11 2007
Isotechnika Inc. Hopes To Begin New Phase In Drug Trial Pending clearance of an investigational new drug application by the U.S. Food and Drug Administration, Isotechnika Inc. hopes to begin a Phase II/ III human clinical trial of its lead immunosuppressive drug, ISA247.
|
|
January 11 2007
Medicure Inc. begins enrolment in single confirmatory Phase III study Medicure Inc. has begun enrolment in a single confirmatory Phase III study to evaluate the cardioprotective effects of its FDA fast tracked product, MC-1.
|
|
January 11 2007
Helix BioPharma Completes Phase II clinical study Helix BioPharma Corp. has completed enrolment and treatment in its Phase II clinical study of Topical Interferon Alpha-2b.
|
|
January 11 2007
Cytochroma Inc. Recruits For Psoriasis Phase II Clinical Trial Cytochroma Inc. has begun recruitment of patients with chronic plaque psoriasis for a Phase II clinical trial.
|
|
January 10 2007
A Practical Guide To Post-Marketing Observational Studies (PMOS) What To Do And What To Avoid
In the spectrum of designs available for the evaluation of medical and, specifically, pharmaceutical interventions, the Post-Marketing Phase IV or Observational Study has been considered as the black sheep of the family. |
|
January 09 2007
Liponex Inc. modifies CRD5 Phase I/II clinical trial protocol Liponex Inc., a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called good cholesterol, announces that it will modify the clinical protocol for its ongoing Phase I/II clinical trial for its lead product, CRD5.
|
|
December 18 2006
Allon Therapeutics presents at IBCs EuroTIDES conference Allon Therapeutics Inc., The Neuro Protection Company, presents a case study during IBC's EuroTIDES 2006 conference: Oligonucleotide, RNAi and Peptides for the Drug Development and Manufacturing Industry in Hamburg, Germany, providing an update on the understanding of how NAP, the core element of Allon's Phase II drug, reaches its target within the central nervous system
|
|
November 27 2006
Isotechnika Inc. Meets Safety And Efficacy Endpoints Isotechnika Inc. has met all safety and efficacy endpoints in a Phase III trial of ISA247 for psoriasis. The SPIRIT trial was extended beyond its initial 24 weeks to give patients the opportunity to continue ISA247 therapy at a 0.3 mg/kg twice daily oral dose for an additional 36 weeks. The extension verified long term safety data while demonstrating continued therapeutic benefit.
|
|
November 27 2006
Allon Therapeutics Inc. Completes Dosing Allon Therapeutics Inc. has completed dosing in a Phase Ib human clinical trial evaluating AL-108 as a treatment for Alzheimer's disease.
|
|
November 27 2006
Theratechnologies completes efficacy phase Theratechnologies has completed the efficacy phase - 26 weeks of treatment - of its first Phase III clinical trial testing TH9507 in HIV-associated lipodystrophy.
|
|
November 27 2006
Finnish National Agency for Medicines Gives Approval To BioMS Medical Corp. The Finnish National Agency for Medicines has given BioMS Medical Corp. approval to begin enrolling patients in Finland into a phase II/III trial of MBP8298, a synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS).
|
|
November 27 2006
Top ranked cancer centre joins Protox clinical trial The University of Texas's world renown M. D. Anderson Cancer Center began treatment of its first patients in an ongoing Phase I clinical trial for Vancouver, B.C.-based Protox Therapeutics Inc.'s PRX302 for localized recurrent prostate cancer.
|
|
November 21 2006
Neuromedix poised to realize next stage of business plan through NeuroMedix Inc. announces that based on the positive pre-clinical development data received to date for its lead product, Minozac, it will now explore licensing or acquisition transactions with a view to maximizing shareholder value.
|
|
November 07 2006
Allon Therapeutics launches $8 million financing Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has engaged a syndicate of agents co-led by Blackmont Capital and Clarus Securities and including Sprott Securities to raise approximately $8 million through a private placement of units priced at $0.80 per unit.
|